OMER Latest Press Releases

-- December 1, 2025 --

Omeros Corporation Announces Closing of Asset Purchase and License Agreement with Novo Nordisk for Omeros' Clinical-Stage MASP-3 Inhibitor Zaltenibart (OMS906) Business Wire 8:30 AM

-- November 13, 2025 --

Omeros Corporation Reports Third Quarter 2025 Financial Results Business Wire 4:11 PM

-- November 11, 2025 --

Omeros Corporation to Announce Third Quarter Financial Results on November 13, 2025 Business Wire 8:30 AM

-- October 16, 2025 --

Omeros Announces Publication Highlighting Survival Benefits in TA-TMA Patients Treated with Narsoplimab Versus a Well-Matched External Control Group Business Wire 8:30 AM

-- October 15, 2025 --

Novo Nordisk and Omeros announce asset purchase and license agreement for Omeros' clinical-stage MASP-3 inhibitor zaltenibart (OMS906) Globe Newswire 8:30 AM

-- September 2, 2025 --

Omeros Announces Publication Highlighting Survival Outcomes in TA-TMA Patients Treated with Narsoplimab Under Its Global Expanded Access Program Business Wire 8:45 AM

-- August 14, 2025 --

Omeros Corporation Reports Second Quarter 2025 Financial Results Business Wire 4:02 PM

-- August 11, 2025 --

Omeros Corporation to Announce Second Quarter Financial Results on August 14, 2025 Business Wire 4:02 PM

-- July 25, 2025 --

Omeros Corporation Announces Pricing of $22 Million Registered Direct Offering Business Wire 8:00 AM

Market Data Delayed 15 Minutes

Questions? Feedback?Olark live chat software